Comparative clinical trial with a new substance, Diftalone, versus indomethacin in 30 patients affected with rheumatoid arthritis

Abstract

During a double-blind, randomized study on 30 patients affected with classic or definite rheumatoid arthritis, the efficacy and safety of treatment with diftalone in a per oral dosage of 500 mg/day were compared with those of indomethacin given orally at doses of 50-75 mg/day initially and 100 mg/day subsequently, for a treatment period of 24 months. In this long-term study, diftalone demonstrated that its effectiveness and safety in the treatment of rheumatoid arthritis are clearly comparable to those of indomethacin.